Prevention of preeclampsia in oocyte donation WOMEN BY THE ADMINISTRATION OF ASPIRIN IN EARLY PREGNANCY

Phase 1

• Conditions: PREECLAMPSIA; Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]

• Registration Number: EUCTR2011-005979-16-ES
• Lead Sponsor: Instituto de Investigación Sanitaria La Fe

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09-14
• Last Update Posted: 6 November 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 136

Inclusion Criteria

Patients over 18 years. - Patients receiving oocyte donation. - Patients who have
become pregnant. - Single or multiple gestations. - To accept the conditions of the
study by signing the appropriate informed consent
single pregnancies
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 372
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Known allergy to ASA. - History of peptic ulcer. - Use of prostaglandin inhibitors
within 10 days before the start of the study. - History of chronic renal disease,
thyroid, liver or heart disease. - Psychiatric or cognitive pathology that prevents the
understanding of the conditions of informed consentKnown allergy to ASA. - History of peptic ulcer. - Use of prostaglandin inhibitors
within 10 days before the start of the study. - History of chronic renal disease,
thyroid, liver or heart disease. - Psychiatric or cognitive pathology that prevents the
understanding of the conditions of informed consent

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified